{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017625","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.537338+00:00","generated_at":"2026-06-02T23:24:52.663258+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Abeona reports preliminary Q1 cash $62.7M; terminates $106M ATM prospectus","bullets":["Preliminary cash, equivalents, and investments of $62.7M as of March 31, 2024.","Terminated June 2023 ATM prospectus covering up to $106M in common shares.","No sales under Sales Agreement until a new prospectus or registration statement is filed.","Sales Agreement itself remains in effect; only the specific supplement is suspended."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017625","json":"https://secwatch.observer/filing/0001493152-24-017625.json","markdown":"https://secwatch.observer/filing/0001493152-24-017625.md","text":"https://secwatch.observer/filing/0001493152-24-017625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/0001493152-24-017625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:24:52.663258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ac1d067d6f4b9da3b054c7d7bc5786c6c01a3bd","claim":"ABEONA THERAPEUTICS INC. reported preliminary financial results for the quarter ended March 31, 2024.","evidence_excerpt":"the Company’s cash, cash equivalents, restricted cash and short-term investments were approximately $62.7 million. This financial information is preliminary and subject to change in connection with the completion of the Company’s financial statements for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/0001493152-24-017625-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}